FREE subscriptions for doctors and students... click here
You have 3 more open access pages.
- BHS guidelines advise that ACEIs and ARBs be used with caution and under
specialist advice in the presence of "renal impairment"
- NICE advises that ACEI (or ARBs) should be initiated under specialist supervision
in patients with plasma creatinine concentration above 150 µmol/L
- there is a risk that these drugs will precipitate acute renal failure as
a result of unrecognised bilateral critical renal vascular disease, by interrupting
the intrarenal production of angiotensin II that normally maintains GFR in
the presence of reduced renal perfusion
- even in the absence of atherosclerotic renal artery stenosis, antihypertensive
drugs can cause reduction in GFR, by reducing renal perfusion; this is particularly
likely in the presence of kidney disease, affecting autoregulation of renal
blood flow
- at what level of deterioration in GFR or creatinine concentration rise should
specialist advice be sought:
- it has been recommended that discussion with a specialist if a patient's
serum creatinine concentration rises by 30% or whose estimated GFR falls
by 20% as an apparent consequence of ACEI/ARB use (1)
- stop renin-angiotensin system antagonists if the serum potassium concentration
increases to 6.0 mmol/litre or more and other drugs known to promote hyperkalaemia
have been discontinued
- following the introduction or dose increase of renin-angiotensin system
antagonists, do not modify the dose if either the GFR decrease from
pretreatment baseline is less than 25% or the serum creatinine increase
from baseline is less than 30%
- if there is a decrease in eGFR or increase in serum creatinine after
starting or increasing the dose of renin-angiotensin system antagonists,
but it is less than 25% (eGFR) or 30% (serum creatinine) of baseline,
repeat the test in 1-2 weeks. Do not modify the renin-angiotensin system
antagonist dose if the change in eGFR is less than 25% or the change in
serum creatinine is less than 30%
- If the eGFR change is 25% or more, or the change in serum creatinine
is 30% or more:
- investigate other causes of a deterioration in renal function,
such as volume depletion or concurrent medication (for example, NSAIDs)
- if no other cause for the deterioration in renal function is found,
stop the renin-angiotensin system antagonist or reduce the dose to
a previously tolerated lower dose, and add an alternative antihypertensive
medication if required
Reference:
- The Renal Association (May
2006).UK CKD Guidelines
- NICE (July 2014). Chronic
kidney disease early identification and management of chronic kidney disease
in adults in primary and secondary care
Last edited 10/2018
Links: